TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
-13.2%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.35B
AUM Growth
+$2.35B
(-15%)
Cap. Flow
+$45.2M
Cap. Flow
% of AUM
1.92%
Top 10 Holdings %
Top 10 Hldgs %
43.47%
Holding
145
New
11
Increased
26
Reduced
10
Closed
4
Top Buys
| 1 |
Medtronic
MDT
|
$32.5M |
| 2 |
Eli Lilly
LLY
|
$23.9M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$23.4M |
| 4 |
SPDR S&P Biotech ETF
XBI
|
$15.2M |
| 5 |
WELL.PRI
Welltower Inc.
WELL.PRI
|
$12.4M |
Top Sells
| 1 |
Johnson & Johnson
JNJ
|
$61.2M |
| 2 |
Teva Pharmaceuticals
TEVA
|
$35.4M |
| 3 |
Illumina
ILMN
|
$13.9M |
| 4 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
$12.5M |
| 5 |
ALR
Alere Inc
ALR
|
$11.6M |
Sector Composition
| 1 | Healthcare | 87.12% |
| 2 | Real Estate | 4.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $214M | 9.11% | 2,331,231 | – | – |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $175M | 7.44% | 1,747,234 +33,600 | +2% | +$3.36M |
|
3
Biogen
BIIB
$19.4B
| $117M | 4.99% | 450,533 | – | – |
|
|
AGN
4
DELISTED
Allergan plc
AGN
| $110M | 4.67% | 409,586 | – | – |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $88.7M | 3.77% | 636,805 | – | – |
|
6
Vertex Pharmaceuticals
VRTX
$100B
| $82.2M | 3.49% | 1,033,503 | – | – |
|
7
Incyte
INCY
$16.5B
| $69.3M | 2.95% | 956,461 +76,000 | +9% | +$5.51M |
|
|
8
Illumina
ILMN
$15.8B
| $56.6M | 2.41% | 348,864 -85,477 | -20% | -$13.9M |
|
9
Regeneron Pharmaceuticals
REGN
$61.5B
| $55.6M | 2.36% | 154,266 | – | – |
|
10
Pfizer
PFE
$141B
| $53.7M | 2.28% | 1,812,011 +9,720 | +0.5% | +$288K |
|
11
UnitedHealth
UNH
$281B
| $52.7M | 2.24% | 409,100 | – | – |
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $49.2M | 2.09% | 596,145 | – | – |
|
13
Amgen
AMGN
$155B
| $48.2M | 2.05% | 321,640 | – | – |
|
|
14
Medtronic
MDT
$119B
| $41.8M | 1.78% | 557,104 +432,760 | +348% | +$32.5M |
|
|
15
Johnson & Johnson
JNJ
$427B
| $40.6M | 1.73% | 375,088 -565,900 | -60% | -$61.2M |
|
16
Merck
MRK
$210B
| $36M | 1.53% | 681,097 | – | – |
|
|
17
Teva Pharmaceuticals
TEVA
$21.1B
| $36M | 1.53% | 671,958 -662,279 | -50% | -$35.4M |
|
|
SHPG
18
DELISTED
Shire pic
SHPG
| $34.7M | 1.47% | 201,713 +29,900 | +17% | +$5.14M |
|
|
MDVN
19
DELISTED
MEDIVATION, INC.
MDVN
| $30.7M | 1.3% | 667,300 | – | – |
|
|
20
Eli Lilly
LLY
$657B
| $30M | 1.28% | 417,167 +331,500 | +387% | +$23.9M |
|
21
Viatris
VTRS
$12.3B
| $28.6M | 1.22% | 617,952 +86,700 | +16% | +$4.02M |
|
22
Agilent Technologies
A
$35.7B
| $28.4M | 1.21% | 713,850 -14,800 | -2% | -$590K |
|
23
HCA Healthcare
HCA
$94.5B
| $26.1M | 1.11% | 334,998 -113,490 | -25% | -$8.86M |
|
24
Humana
HUM
$36.5B
| $23.7M | 1.01% | 129,300 | – | – |
|
|
25
Jazz Pharmaceuticals
JAZZ
$7.75B
| $23.4M | 0.99% | +179,091 | New | +$23.4M |
|